New vaccine aims to fight EBV-Linked blood cancers
NCT ID NCT07525024
First seen Apr 21, 2026 · Last updated Apr 25, 2026 · Updated 2 times
Summary
This study looks at a new vaccine called KSD-101 for people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine is designed to train the body's immune system to attack cancer cells. Researchers will track how many patients' tumors shrink or disappear, and monitor for side effects. The goal is to see if this vaccine can help control these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV ASSOCIATED LYMPHOID NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin-Hainan Hospital，Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
Qionghai, Hainan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.